JP2010508349A - ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法 - Google Patents

ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法 Download PDF

Info

Publication number
JP2010508349A
JP2010508349A JP2009535306A JP2009535306A JP2010508349A JP 2010508349 A JP2010508349 A JP 2010508349A JP 2009535306 A JP2009535306 A JP 2009535306A JP 2009535306 A JP2009535306 A JP 2009535306A JP 2010508349 A JP2010508349 A JP 2010508349A
Authority
JP
Japan
Prior art keywords
dcp
administering
effective amount
subject
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009535306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508349A5 (enExample
Inventor
モヘノ，フィリップ
フレイデラー，ウォルフガング
Original Assignee
サンアールエックス ファーマスーティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンアールエックス ファーマスーティカルズ，インク． filed Critical サンアールエックス ファーマスーティカルズ，インク．
Publication of JP2010508349A publication Critical patent/JP2010508349A/ja
Publication of JP2010508349A5 publication Critical patent/JP2010508349A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2009535306A 2006-10-30 2007-10-30 ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法 Pending JP2010508349A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86354706P 2006-10-30 2006-10-30
PCT/US2007/023012 WO2008054793A2 (en) 2006-10-30 2007-10-30 Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon

Publications (2)

Publication Number Publication Date
JP2010508349A true JP2010508349A (ja) 2010-03-18
JP2010508349A5 JP2010508349A5 (enExample) 2010-11-11

Family

ID=39344907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535306A Pending JP2010508349A (ja) 2006-10-30 2007-10-30 ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法

Country Status (7)

Country Link
US (2) US7662820B2 (enExample)
EP (1) EP2094715B1 (enExample)
JP (1) JP2010508349A (enExample)
CN (1) CN101663308A (enExample)
CA (1) CA2668262A1 (enExample)
ES (1) ES2394227T3 (enExample)
WO (1) WO2008054793A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685780T3 (es) * 2002-08-22 2018-10-11 Sumitomo Dainippon Pharma Co., Ltd. Agente para el tratamiento de esquizofrenia
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
EP1726952A4 (en) * 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
EP2094715B1 (en) * 2006-10-30 2012-08-29 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
CA2712118A1 (en) * 2008-01-18 2009-07-23 Sanrx Pharmaceuticals, Inc. Pterin based therapies for inflammatory conditions
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
WO2013116238A1 (en) * 2012-01-30 2013-08-08 Sanrx Pharmaceuticals, Inc. Calcium folate (cafolate) and therapeutic methods based thereon
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527518A (ja) * 1998-10-22 2002-08-27 フィリップ・ビー・ビー・モヘノ 新規なプテリン抗新生物薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2094715B1 (en) * 2006-10-30 2012-08-29 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527518A (ja) * 1998-10-22 2002-08-27 フィリップ・ビー・ビー・モヘノ 新規なプテリン抗新生物薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013003429; Ｍｏｌ．　Ｃｒｙｓｔ．　Ｌｉｑ．　Ｃｒｙｓｔ． Ｖｏｌ．２７６, 1996, Ｐ．２２９-２３５ *
JPN6013003430; Ｉｎｏｒｇ．　Ｃｈｅｍ． Ｖｏｌ．３４, 1995, Ｐ．３３６７-３３７０ *

Also Published As

Publication number Publication date
CA2668262A1 (en) 2008-05-08
EP2094715A4 (en) 2010-04-28
US20100105692A1 (en) 2010-04-29
EP2094715B1 (en) 2012-08-29
WO2008054793A2 (en) 2008-05-08
US20080166355A1 (en) 2008-07-10
WO2008054793A3 (en) 2008-08-28
ES2394227T3 (es) 2013-01-23
US7662820B2 (en) 2010-02-16
CN101663308A (zh) 2010-03-03
EP2094715A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
US7662820B2 (en) Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon
US11351205B2 (en) Microbiome related immunotherapies
WO2015161762A1 (zh) 环二核苷酸cGAMP在抗肿瘤中的应用
KR101578481B1 (ko) 증식성 질환을 치료하기 위하여 ｎ－（5－ｔｅｒｔ－부틸－아이소제이졸－3－일）－ｎ′－｛4－［7－（2－몰포린－4－일－에톡시）이미다조［2,1－ｂ］［1,3］벤조티아졸－2－일］페닐｝우레아를 투여하는 방법
TW201513864A (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
CN112272552A (zh) 包含糖皮质激素受体拮抗剂的固体形式和制剂及其用途
JP2009515901A (ja) ｍＴＯＲ阻害剤投与によるがん患者の治療
WO2017162055A1 (zh) 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
CN101429201A (zh) 柠檬酸小檗胺盐及制备方法和应用
KR20190047628A (ko) 다공성 자성 나노입자 기반 약물 전달체 및 그 제조방법
WO2016001907A1 (en) Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JPWO2010110223A1 (ja) 抗腫瘍作用を有するフコイダン
TW201728328A (zh) 針對具有重度腎功能障礙之癌症患者之治療方法
US20170087125A1 (en) Flavonoid compositions for the treatment of cancer
TW202245780A (zh) 用於治療神經膠質母細胞瘤之方法
CN114222580B (zh) 一种预防和/或治疗卵巢癌的多肽药物及其用途
WO2026020558A1 (zh) 小分子药物联用在增强低氧条件下nk细胞的代谢、杀伤能力中的应用
CN102617679B (zh) 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
WO1992004028A1 (en) Antineoplastic effect potentiator and antineoplastic agent
CN114939122B (zh) 天然植物来源的联合抗肿瘤药物组合物
CN105078944A (zh) Isopaucifloral F在制备抗骨质疏松药物中的用途
CN113993515B (zh) 使用藏红花酸治疗实体肿瘤的方法
CN102451183B (zh) 一种孕甾双烯醇酮类化合物在制备抗肿瘤药物中的应用
HK1139952A (en) Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
CN104434948A (zh) 一种抗胰腺癌的药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702